MELEMA Pharma GmbH, a private biopharmaceutical company, is focusing on the development of natural compounds 4.0.4having the potential to activate the patient’s own immune system. A substantial medical challenge for the company is the immuno-oncology.

MELEMA Pharma, set up in 2013, develops its drug candidates to Proof of Concept, and then bring in partners from academia and industry for the final stages of product development and commercialization.

Lead product is the immunepotentiator Aviscumine (ME-503), a therapeutic protein which recently completed a Phase II study in patients with refractory metastatic melanoma (stage IV) and for which the further clinical development (multi-national) is in preparation.


The enterprise, which was set up in 2013, acquired all the assets and programmes of CYTAVIS BioPharma GmbH, a biopharmaceutical company that was already working with Aviscumine.


Olaf R. Schneider, CEO (o.schneider@nullmelemapharma.com)

is the CEO of MELEMA Pharma GmbH. Mr. Schneider has acquired a wide range of expertise in business developement and business structuring by working for a management consultancy and a private equity fund with a strong focus on biotech and health care.

Dr. Hans Lentzen, Wissenschaftlicher Geschäftsführer (h.lentzen@nullmelemapharma.com)

is the Chief Scientific Officer of MELEMA Pharma GmbH. He is pharmacist and pharmacologist and has more than 20 years of management experience in the R&D area of the pharmaceutical and biotechnological industry. He was the former Head of the R&D Division of MADAUS AG, Cologne, and is one of the founders of MELEMA. In January 1999, he was awarded the ”Cologne Innovation Prize 1998” for the idea, the concept as well as the research and development work on the Aviscumine project.

Advisory Board and Cooperations

Pharmedartis GmbH, Forckenbeckstr. 6, 52074 Aachen,  Germany

Pharmedartis GmbH (PMA) is a biotechnology company founded by experienced scientists of the German Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Aachen. As specialist in recombinant technologies and protein production PMA is responsible for the construction of cell banks for the appropriate gene expression and for the GMP-manufacturing of the drug substances from MELEMA Pharma GmbH.

Together with Professor Dr. Ulrike Naumann, Laboratory for Molecular Neuro-Oncology, Hertie Institute for Clinical Brain Research and Center Neurology, University of Tübingen and Professor Dr. Michel Mittelbronn, Goethe-University Frankfurt, Institute of Neurology (Edinger Institute) in-vitro and in-vivo studies investigating the effect of Aviscuminum (ME-503) on the invasive destructive growth of glioblastoma (mouse model) are conducted.

MELEMA and Lonza Enter into a Development Services Agreement to Further Progress MELEMA’s Cancer Therapeutic, ME-503

Hamburg, Germany and Basel, Switzerland, 21 July 2015 – Lonza and MELEMA Pharma GmbH announced today that they have entered into a service agreement for protein assessment services on MELEMA’s leading cancer therapeutic, ME-503. Under the agreement, Lonza will investigate the strong ME-503 induced DC stimulation and T cell responses. Analysis of T cell responses is a frequently used tool to monitor the activation of the immune system.

About Lonza

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Further information can be found at www.lonza.com.